Biblio

Author Title Type [ Year(Asc)]
Filters: Author is von Bubnoff, Nikolas  [Clear All Filters]
2024
Lübke J, Schmid A, Christen D, Elberink HNGOude, Span LFR, Niedoszytko M, Górska A, Lange M, Gleixner KV, Hadzijusufovic E, et al. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM. Blood Adv. 2024.
2023
Xie X, Patnana PKumar, Frank D, Schütte J, Al-Matary Y, Künstner A, Busch H, Ahmed H, Liu L, Engel DR, et al. Dose-dependent effect of GFI1 expression in the reconstitution and the differentiation capacity of HSCs. Front Cell Dev Biol. 2023;11:866847.
Patnana PKumar, Liu L, Frank D, Nimmagadda SChary, Behrens M, Ahmed H, Xie X, Liebmann M, Wei L, Gerdemann A, et al. Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells. Br J Haematol. 2023.
2022
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, et al. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022.
Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, et al. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022;172:107-118.
2021
Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, Elberink HOude, van Anrooij B, Niedoszytko M, Lange M, et al. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). J Invest Dermatol. 2021.
2020
Waldeck S, Rassner M, Keye P, Follo M, Herchenbach D, Endres C, Charlet A, Andrieux G, Salzer U, Boerries M, et al. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML. Mol Oncol. 2020.
Javorniczky NRebeka, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, et al. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leuk Res. 2020;98:106454.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020.
2016
Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. PLoS One. 2016;11(8):e0161012.
2014
Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N. Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells. PLoS One. 2014;9(11):e112318.